Literature DB >> 25096911

Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates.

Giovam Battista Rini1, Delia Sprini, Silvia Migliaccio, Stefania Basili, Rocky Strollo, Francesco Dieli, Nicola Napoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25096911     DOI： 10.1007/s12020-014-0303-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

1.  Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

Authors:  Francesco Dieli; Nicola Gebbia; Fabrizio Poccia; Nadia Caccamo; Carla Montesano; Fabio Fulfaro; Carlo Arcara; Maria R Valerio; Serena Meraviglia; Caterina Di Sano; Guido Sireci; Alfredo Salerno
Journal:  Blood       Date:  2003-09-15       Impact factor: 22.113

Review 2.  Alternative bisphosphonate targets and mechanisms of action.

Authors:  Jack F Bukowski; Christopher C Dascher; Hiranmoy Das
Journal:  Biochem Biophys Res Commun       Date:  2005-03-18       Impact factor: 3.575

3.  In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation.

Authors:  V Ferlazzo; C Sferrazza; N Caccamo; G Di Fede; G Di Lorenzo; M D'Asaro; S Meraviglia; F Dieli; G Rini; A Salerno
Journal:  Int J Immunopathol Pharmacol       Date:  2006 Apr-Jun       Impact factor: 3.219

4.  Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.

Authors:  Reina Armamento-Villareal; Nicola Napoli; Vinita Panwar; Deborah Novack
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

5.  Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

Authors:  Martin Wilhelm; Volker Kunzmann; Susanne Eckstein; Peter Reimer; Florian Weissinger; Thomas Ruediger; Hans-Peter Tony
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

6.  Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.

Authors:  Keith Thompson; James E Dunford; Frank H Ebetino; Michael J Rogers
Journal:  Biochem Biophys Res Commun       Date:  2002-01-18       Impact factor: 3.575

Review 7.  Biochemical and molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers; Julie C Crockett; Fraser P Coxon; Jukka Mönkkönen
Journal:  Bone       Date:  2010-11-26       Impact factor: 4.398

8.  In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

Authors:  S Meraviglia; M Eberl; D Vermijlen; M Todaro; S Buccheri; G Cicero; C La Mendola; G Guggino; M D'Asaro; V Orlando; F Scarpa; A Roberts; N Caccamo; G Stassi; F Dieli; A C Hayday
Journal:  Clin Exp Immunol       Date:  2010-05-10       Impact factor: 4.330

Review 9.  Gammadelta T cell modulation in anticancer treatment.

Authors:  Nadia Caccamo; Francesco Dieli; Serena Meraviglia; Giuliana Guggino; Alfredo Salerno
Journal:  Curr Cancer Drug Targets       Date:  2010-02       Impact factor: 3.428

10.  Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

Authors:  Reina Armamento-Villareal; Nicola Napoli; Kathryn Diemer; Marcus Watkins; Roberto Civitelli; Steven Teitelbaum; Deborah Novack
Journal:  Calcif Tissue Int       Date:  2009-06-23       Impact factor: 4.333
  10 in total
  1 in total

1.  Effects of denosumab on peripheral lymphocyte subpopulations.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Francesco Ghellere; Gaia Tripi; Riccardo Ortolani; Roberta Zanotti; Davide Gatti
Journal:  Endocrine       Date:  2015-08-20       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.